Prothena | PRTA - Sales Revenues


Prothena reported $51.08M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Exelixis USD 628.69M 17.89M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026